SG11201402780UA - Influenza a virus specific antibodies - Google Patents
Influenza a virus specific antibodiesInfo
- Publication number
- SG11201402780UA SG11201402780UA SG11201402780UA SG11201402780UA SG11201402780UA SG 11201402780U A SG11201402780U A SG 11201402780UA SG 11201402780U A SG11201402780U A SG 11201402780UA SG 11201402780U A SG11201402780U A SG 11201402780UA SG 11201402780U A SG11201402780U A SG 11201402780UA
- Authority
- SG
- Singapore
- Prior art keywords
- influenza
- specific antibodies
- virus specific
- virus
- antibodies
- Prior art date
Links
- 241000712431 Influenza A virus Species 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11191783 | 2011-12-02 | ||
| PCT/NL2012/050851 WO2013081463A2 (en) | 2011-12-02 | 2012-12-03 | Influenza a virus specific antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201402780UA true SG11201402780UA (en) | 2014-10-30 |
Family
ID=47297373
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201402780UA SG11201402780UA (en) | 2011-12-02 | 2012-12-03 | Influenza a virus specific antibodies |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9718874B2 (en) |
| EP (1) | EP2785737A2 (en) |
| JP (1) | JP6325451B2 (en) |
| KR (1) | KR20140112495A (en) |
| AU (3) | AU2012346669B2 (en) |
| CA (1) | CA2892992A1 (en) |
| SG (1) | SG11201402780UA (en) |
| WO (1) | WO2013081463A2 (en) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007067032A1 (en) | 2005-12-09 | 2007-06-14 | Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam | Means and methods for influencing the stability of cells |
| AU2006323315B2 (en) | 2005-12-09 | 2014-02-20 | Academisch Medisch Centrum Bij De Universiteit Van Amsterdam | Means and methods for influencing the stability of antibody producing cells |
| DK2454283T3 (en) | 2009-07-15 | 2018-05-07 | Aimm Therapeutics Bv | METHODS AND PROCEDURES FOR MANUFACTURING HIGH EFFICIENCY ANTIBODIES |
| PL2646466T3 (en) | 2010-12-02 | 2017-09-29 | Aimm Therapeutics B.V. | Means and methods for producing high affinity antibodies |
| US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
| BR112016014072B1 (en) | 2013-12-17 | 2023-12-26 | Kling Biotherapeutics B.V. | ISOLATED, SYNTHETIC OR RECOMBINANT HUMAN ANTIBODY, OR A FUNCTIONAL PART THEREOF, ISOLATED NUCLEIC ACID MOLECULE, VECTOR, COMPOSITION, USE OF AN ANTIBODY OR FUNCTIONAL PART, OR A NUCLEIC ACID MOLECULE OR A VECTOR, AND, METHODS FOR PRODUCING AN ANTIBODY OR FUNCTIONAL PART, AND TO DETERMINE WHETHER AML CELLS OR LYMPHOMA CELLS OR MULTIPLE MYELOMA CELLS OR NON-HODGKIN LYMPHOMA B CELLS ARE PRESENT IN A SAMPLE |
| US10611829B2 (en) | 2014-01-31 | 2020-04-07 | Aimm Therapeutics B.V. | Means and methods for producing stable antibodies |
| KR101582490B1 (en) * | 2014-04-14 | 2016-01-19 | 아이디바이오 주식회사 | Novel virus vaccine to form cross-protection against multiple subtypes of influenza viruses |
| TWI702229B (en) | 2014-12-19 | 2020-08-21 | 美商再生元醫藥公司 | Human antibodies to influenza hemagglutinin |
| WO2016209079A1 (en) | 2015-06-24 | 2016-12-29 | Aimm Therapeutics B.V. | Aml antigens and uses thereof |
| EP3374390A1 (en) | 2015-11-13 | 2018-09-19 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
| CN106928350B (en) * | 2015-12-30 | 2020-11-03 | 中国科学院天津工业生物技术研究所 | Influenza virus antibody, preparation method and application thereof |
| US11781112B2 (en) | 2016-03-06 | 2023-10-10 | Kareem Thomas Robinson | Method of generating antigen-specific immunological memory in a subject that rejects classical vaccines |
| WO2019067884A1 (en) * | 2017-09-28 | 2019-04-04 | The Children's Medical Center Corporation | Molecular grafting of complex, broadly neutralizing antibody epitopes |
| CA3088194A1 (en) | 2018-01-26 | 2019-08-01 | Regeneron Pharmaceuticals, Inc. | Human antibodies to influenza hemagglutinin |
| CN113924147A (en) | 2019-03-25 | 2022-01-11 | 威特拉公司 | Compositions and methods for treating and preventing influenza |
| MX2022008391A (en) | 2020-01-10 | 2022-09-29 | Kling Biotherapeutics B V | Epithelial cadherin-specific antibodies. |
| CN111298101B (en) * | 2020-02-21 | 2023-05-30 | 佛山科学技术学院 | Application of antibacterial peptide PG-1 in inhibiting avian influenza virus |
| JP2023540373A (en) * | 2020-09-08 | 2023-09-22 | ノヴェルジェン カンパニー リミテッド | Antiviral composition against influenza A virus |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001062907A1 (en) | 2000-02-22 | 2001-08-30 | Medical & Biological Laboratories Co., Ltd. | Antibody library |
| AU2003225976A1 (en) | 2002-03-26 | 2003-10-13 | Centocor, Inc. | Anti-tnf antibodies, compositions, methods and uses |
| AU2006323315B2 (en) | 2005-12-09 | 2014-02-20 | Academisch Medisch Centrum Bij De Universiteit Van Amsterdam | Means and methods for influencing the stability of antibody producing cells |
| MX2009002174A (en) * | 2006-09-07 | 2009-03-12 | Crucell Holland Bv | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof. |
| RU2448979C2 (en) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Human antibodies to delta-like human ligand-4 |
| ITTO20080204A1 (en) * | 2008-03-17 | 2009-09-18 | Pomona Biotechnologies Llc | MONOCLONAL ANTIBODIES ACTIONS TO REACT WITH A PLURALITY OF SUBTIPS OF THE INFLUENTIAL VIRUS A |
| US8871207B2 (en) | 2008-07-25 | 2014-10-28 | Humabs, LLC | Neutralizing anti-influenza A virus antibodies and uses thereof |
| CN102216327A (en) | 2008-07-25 | 2011-10-12 | 生物医学研究所 | Neutralizing anti-influenza a virus antibodies and uses thereof |
| WO2010087994A2 (en) | 2009-01-30 | 2010-08-05 | Whitehead Institute For Biomedical Research | Methods for ligation and uses thereof |
| ES2934102T3 (en) * | 2009-05-11 | 2023-02-16 | Janssen Vaccines & Prevention Bv | Human binding molecules that can neutralize the H3N2 influenza virus and uses thereof |
| EP2435475B1 (en) | 2009-05-26 | 2018-10-17 | Icahn School of Medicine at Mount Sinai | Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof |
| CA2849668A1 (en) | 2010-03-08 | 2011-09-15 | Celltrion, Inc. | Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a viruses |
| EA029198B1 (en) | 2010-03-26 | 2018-02-28 | Помона Ричерка С.Р.Л. | FULL-LENGTH IMMUNOGLOBULINS OF THE IgG ISOTYPE CAPABLE OF RECOGNIZING A HETEROSUBTYPE NEUTRALIZING EPITOPE ON THE HEMAGGLUTININ STEM REGION AND THEIR USE AS ANTI-INFLUENZA MEDICAMENT |
-
2012
- 2012-12-03 SG SG11201402780UA patent/SG11201402780UA/en unknown
- 2012-12-03 EP EP12798020.9A patent/EP2785737A2/en not_active Withdrawn
- 2012-12-03 WO PCT/NL2012/050851 patent/WO2013081463A2/en active Application Filing
- 2012-12-03 JP JP2014544698A patent/JP6325451B2/en active Active
- 2012-12-03 US US14/362,210 patent/US9718874B2/en active Active - Reinstated
- 2012-12-03 KR KR1020147018417A patent/KR20140112495A/en active IP Right Grant
- 2012-12-03 AU AU2012346669A patent/AU2012346669B2/en active Active
- 2012-12-03 CA CA2892992A patent/CA2892992A1/en not_active Abandoned
-
2017
- 2017-07-10 US US15/645,399 patent/US20170313766A1/en not_active Abandoned
- 2017-08-18 AU AU2017216562A patent/AU2017216562A1/en not_active Abandoned
-
2021
- 2021-10-05 AU AU2021245146A patent/AU2021245146A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP6325451B2 (en) | 2018-05-16 |
| US20150010566A1 (en) | 2015-01-08 |
| KR20140112495A (en) | 2014-09-23 |
| US20170313766A1 (en) | 2017-11-02 |
| CA2892992A1 (en) | 2013-06-06 |
| US9718874B2 (en) | 2017-08-01 |
| AU2021245146A1 (en) | 2021-10-21 |
| WO2013081463A2 (en) | 2013-06-06 |
| AU2017216562A1 (en) | 2017-09-07 |
| WO2013081463A3 (en) | 2013-11-14 |
| JP2015506668A (en) | 2015-03-05 |
| EP2785737A2 (en) | 2014-10-08 |
| AU2012346669A1 (en) | 2014-07-24 |
| AU2012346669B2 (en) | 2017-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201402780UA (en) | Influenza a virus specific antibodies | |
| EP2663334A4 (en) | Antibodies directed against influenza | |
| DK3447131T3 (en) | INFLUENZA A VIRUS MUTANTS | |
| GB201115214D0 (en) | Influenza virus antibody compositions | |
| EP2768858A4 (en) | Antibodies directed against influenza | |
| HUE051756T2 (en) | Neutralizing anti-influenza a virus antibodies and uses thereof | |
| GB201103955D0 (en) | Antibodies | |
| GB201112056D0 (en) | Antibodies | |
| EP2795464A4 (en) | Enabling efficient nested virtualization | |
| HK1202442A1 (en) | Vaccines against hpv hpv | |
| HK1200845A1 (en) | Influenza hemagglutinin variants | |
| IL231132A0 (en) | Viral clearnce methods | |
| EP2833147A4 (en) | Detection kit for influenza a virus | |
| HK1202924A1 (en) | Assay for influenza virus hemagglutinins | |
| GB2502470B (en) | A stopper | |
| EP2714074A4 (en) | Anti-emr1 antibodies | |
| GB201122401D0 (en) | A clip | |
| AU2011902660A0 (en) | A Vaccine | |
| ZA201206982B (en) | A clip | |
| GB201103150D0 (en) | A clip | |
| BR302012002514S1 (en) | BOTTLE APPLICATION | |
| BR302012000982S1 (en) | BOTTLE APPLICATION | |
| BR302012000983S1 (en) | BOTTLE APPLICATION | |
| GB201102754D0 (en) | A reflector | |
| BRDI7103373S (en) | BOTTLE APPLICATION |